IQVIA Holdings Inc. $IQV Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 49.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 226,794 shares of the medical research company’s stock after selling 220,525 shares during the period. Candriam S.C.A.’s holdings in IQVIA were worth $38,677,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA during the fourth quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the 4th quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new stake in IQVIA during the 4th quarter worth $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the 4th quarter worth $28,000. Finally, Activest Wealth Management increased its stake in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 0.4%

NYSE IQV opened at $208.13 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market capitalization of $34.74 billion, a P/E ratio of 25.79, a P/E/G ratio of 1.79 and a beta of 1.20. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The firm has a 50-day moving average price of $181.62 and a 200 day moving average price of $188.78.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the company earned $2.70 EPS. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IQV shares. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Robert W. Baird boosted their price target on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a research note on Monday. Finally, Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $224.82.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.